|
October 1, 2005
By:
Kashif Chaudhry, Anne Love
Data suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.
|
|
October 1, 2005
By:
Steve Tarnoff
The pharmaceutical industry devotes more of its promotional budget to samples than anything else, unless you count the army of sales representatives that delivers them. This year, the average wholesale price of samples passed out to doctors will approach $15 billion—roughly twice the value of samples five years ago. And although few in the industry have come to grips with it, the federal regulations governing this enormous investment have undergone drastic changes.
|
|
October 1, 2005
By:
Jill Van Den Bos
To get along with the CFO, drug companies need to express more data in units that a health plan can integrate into its own internal actuarial analysis. The financial decision makers at a health plan want to know how a new drug affects the value of expected claims on the whole.
|
|
October 1, 2005
By:
Patrick Clinton
Think of the role compliance plays in your job. Now imagine that level of concern increased by 25 percent, 50, or even more. That's what pharma has to look forward to in the next few years, as the effects of old regulatory initiatives, such as 21 CFR Part 11 and Sarbanes Oxley, start fully kicking in—and as we experience the as-yet-unknown regulatory fallout of the new concern with drug safety. It's no surprise that a great portion of this volume of Pharm Exec's Successful Product Manager's Handbook series is given over to compliance.
|
|
October 1, 2005
By:
Christopher Lisanti, Pat Pesanello
As the industry thinks about new sales force models, it should look beyond ROI numbers, toward a new paradigm that not only works for pharma, but also for its customers.
|
|
October 1, 2005
By:
Alana Klein
The client-agency relationship is a product of its environment. Chock-full of regulatory requirements, scandals, and heightened FDA scrutiny, the current environment leaves much to be desired. But this is hardly news for the pharma industry.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
